AnginaGRASPNCT07359287
Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care
A study testing Antibiotic prescribing according to guidelines in people with Angina and Acute Bronchiolitis, run by University Hospital, Caen at 1 site in France.
Trial summary
Antimicrobial resistance (AMR), considered one of the greatest global threats by the WHO, justifies the development of initiatives to promote appropriate antibiotic use-especially in primary care, where most antibiotics in France are prescribed and where misuse remains common. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Angina, Acute Bronchiolitis, Acute Bronchitis
- What is being tested?
- Antibiotic prescribing according to guidelines
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,500 participants
- Where
- 1 siteFrance
- Study dates
- 1 Dec 2025to 1 Sep 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patient seen in consultation for an upper or lower respiratory tract infection (Angina, Acute bronchiolitis, Acute bronchitis, COPD exacerbation (AECOPD), Laryngitis, Acute otitis media (AOM), Serous or congestive otitis, Viral respiratory infection (e.g., influenza), Community-acquired pneumonia (CAP), Rhinitis / Nasopharyngitis, Acute sinusitis)
Who cannot join
- Patient under legal protection
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU CAEN Normandie
Caen, 14000
François FOURNEL, head of project, +33231065488, fournel-f@chu-caen.fr
About this study
Official title: Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care: A Cluster-Randomized Trial
Antimicrobial resistance (AMR), considered one of the greatest global threats by the WHO, justifies the development of initiatives to promote appropriate antibiotic use-especially in primary care, where most antibiotics in France are prescribed and where misuse remains common.
We are proposing a cluster-randomized controlled trial to evaluate the effectiveness of a bimodal intervention combining: (1) improved communication about the circulation of respiratory viruses, and (2) strengthened collaborative practices between general practitioners and pharmacists through a multidisciplinary protocol aimed at verifying that prescribed treatment durations comply with guidelines.
Read more
The study will include six primary care practices (24 physicians), with three practices in each study arm.
The aim of this project is to assess whether the bimodal intervention can reduce the duration of antibiotic treatments for upper and lower respiratory tract infections. The first component (a "viral infection prescription" tool) focuses on reducing unnecessary treatment initiation, while the second (pharmacist-led review) aims to shorten excessive prescription durations.
- Conditions
- Angina, Acute Bronchiolitis, Acute Bronchitis, COPD Exacerbation (AECOPD), Laryngitis, Acute Otitis Media (AOM)
- Being tested
- Antibiotic prescribing according to guidelines
- Keywords
- Upper respiratory tract infection, Lower respiratory tract infection
- Medical subject headings
- Angina Pectoris, Bronchitis, Laryngitis, Otitis Media, Influenza, Human, Community-Acquired Pneumonia, Rhinitis, Nasopharyngitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Antibiotic prescribing according to guidelinesOther
If necessary, the general practitioner prescribes antibiotics to patients consulting for an upper or lower respiratory tract infection, according to the guidelines.
| Study group | Role | What they receive |
|---|---|---|
| Control group | No intervention | The primary care practices in the control group do not receive any intervention and continue patient management according to their usual practices. |
| Intervention group | Experimental | For the intervention group, two planned interventions will be planed and applied to the primary care practices:
1. Use of the OPIV (Viral Infection Prescription Tool).
2. A multidisciplinary collaboration protocol between general practitioners and pharmacists to evaluate antibiotic treatment durations. This intervention aims to strengthen collaborative practices. If a prescribed duration does not comply with recommendations, the pharmacist will discuss it with the prescriber, and the duration will be adjusted accordingly." Receives: Other: Antibiotic prescribing according to guidelines |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of antibiotic treatment days prescribed for upper and lower respiratory tract infections.
The primary outcome of the study will be the number of antibiotic treatment days prescribed for upper and lower respiratory tract infections. This outcome is a composite measure reflecting the impact of both interventions. Antibiotic duration will be assessed by running a query in the electronic medical record system of the participating primary care practices. The primary outcome will be evaluated at the baseline.
Measured: The primary outcome is measured at the time of prescription (i.e. at the baseline)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2026
- Study start1 Dec 2025
- Primary completion1 Jun 2026 (estimated)
- Study completion1 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AnginaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 4,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Caen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07359287
- Sponsor's protocol ID
- 24-0171
- Acronym
- GRASP
- Status last verified
- Dec 2025
- First submitted
- 12 Dec 2025
- Last updated
- 22 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No